gsoldi,,2019-06-03 14:38:00,0.55,NH no reverse split yet
AuntMarie,True,2019-06-03 10:53:00,0.5491,CYTR NK NH IMPORTANT connect the dots needed heregood news from my scientific perspective ascopubsorgdoiabs10120
AuntMarie,True,2019-06-03 10:51:00,0.5405,CYTR NK NH NantWorks LLC today announced that its affiliate companies NantHealthNH Inc a leading nextgeneration evidencebased personalized healthcare company and NantOmics LLC the leader in molecular analyses will present data on the association between increased TMB and increased PDL1 expression with the presence of SDHFH mutations in a variety of tumors using 3461 paired tumornormal whole exome sequences from the NantHealthNH clinical cases database to look into the potential therapeutic role for inhibition of PD1PDL1 pathway in these tumors during the cancer prevention hereditary genetics and epidemiology session at the ASCO 2019 Annual Meeting an event bringing together more than 32000 global oncology professionals from May 31June 4 2019 at McCormick Place in Chicago Illinois NantHealthNH and NantOmics conducted this study with researchers from Virginia Commonwealth Universitys Massey Cancer Center
